Dyadic International, Inc.
DYAI · NASDAQ
Market closed$1.26$0.070000 (+5.88%)After hours $1.19 · -5.56%
Key statistics
Previous close$1.19
Open$1.17
Day high$1.31
Day low$1.17
52-week high$1.35
52-week low$0.650000
Market cap45.91M
Volume135.48K
Average volume309.92K
P/E ratio-5.48
Forward P/E—
EPS-0.23
Dividend yield0.00%
Market context
Why it moved
DYAI shares rose on broad positive market sentiment driven by continued strength in AI and innovation-driven sectors, attracting renewed investor interest and buying momentum in small-cap biotech stocks.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 16, 2026Dyadic’s New Enzyme Program Targets Pulp, Paper and BiofuelsGlobeNewswire · July 16, 2026Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme ProgramInvesting.com South Africa · July 16, 2026Dyadic expands bio-industrial pipeline with cellulose enzyme By Investing.comSimply Wall Street · July 11, 2026Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before LongStock Titan · July 7, 2026Dyadic says its C1 platform can make antibodies and vaccines fasterQuiver Quantitative · July 7, 2026Dyadic International Highlights Progress in Global Health Collaborations for Its C1 Protein Production PlatformMoomoo · July 7, 2026Dyadic International Progresses Multiple Protein Production PartnershipsStock Titan · June 22, 2026Dyadic (NASDAQ: DYAI) investors OK reverse split, pay plan and auditor Mt Newswire · July 7, 2026Dyadic International Progresses Multiple Protein Production Partnerships Mt Newswire · June 29, 2026Dyadic International Receives Japan Patent Allowance for Recombinant Protein Expression Technology Benzinga · June 29, 2026Dyadic Announces Japan Patent Office Allowance Of Claims Covering Its Proprietary Thermothelomyces Heterothallica Recombinant Protein Expression Technology Benzinga · June 15, 2026Dyadic Highlights Increasing Interest In Proprietary C1 Protein Production Platform As Global Infectious Disease Preparedness Efforts Intensify In Response To Ongoing Bundibugyo Ebola Virus Outbreak Benzinga · May 28, 2026Dyadic's Applied Biosolutions Unit Collaborates With Scripps Research To Evaluate Monoclonal Antibody And Vaccine Candidates Targeting Hantaviruses, Including Andes Virus Benzinga · May 13, 2026Transcript: Dyadic International Q1 2026 Earnings Conference Call Benzinga · May 13, 2026Dyadic International Q1 EPS $(0.05) Misses $(0.04) Estimate, Sales $1.111M Beat $900.000K Estimate Benzinga · March 30, 2026Dyadic International Gets Nasdaq Warning Over Listing Rules, Faces Delisting Risk